<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neomycin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neomycin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Neomycin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9686" href="/d/html/9686.html" rel="external">see "Neomycin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11371" href="/d/html/11371.html" rel="external">see "Neomycin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709169"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Systemic absorption of neomycin occurs following oral administration, and toxic reactions may occur. Patients treated with neomycin should be under close clinical observation because of the potential toxicity associated with the use of neomycin. Neurotoxicity (including ototoxicity) and nephrotoxicity following the oral use of neomycin sulfate have been reported, even when used in recommended doses. The potential for nephrotoxicity, permanent bilateral auditory ototoxicity, and sometimes vestibular toxicity, is present in patients with healthy renal function when treated with higher doses of neomycin or for longer periods than recommended. Serial, vestibular and audiometric tests, as well as tests of renal function, should be performed (especially in high-risk patients). The risk of nephrotoxicity and ototoxicity is greater in patients with impaired renal function. Ototoxicity is often delayed in onset, and patients developing cochlear damage will not have symptoms during therapy to warn them of developing eighth nerve destruction, and total or partial deafness may occur long after neomycin has been discontinued.</p>
<p style="text-indent:-2em;margin-left:2em;">Other factors which increase the risk of toxicity are advanced age and dehydration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular blockade:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular blockage and respiratory paralysis have been reported following the oral use of neomycin. The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics; neuromuscular-blocking agents such as tubocurarine, succinylcholine, decamethonium; or massive transfusions of citrate anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but mechanical respiratory assistance may be necessary.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Concurrent therapy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concurrent or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive.</p>
<p style="text-indent:-2em;margin-left:2em;">The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously (IV), diuretics may enhance neomycin toxicity by altering the antibiotic concentration in serum and tissue.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048863"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Ammonium Detoxicant</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Aminoglycoside</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Topical</span>;</li>
<li>
<span class="list-set-name">Hyperammonemia Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462514"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosage expressed in terms of <b>neomycin sulfate</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0f53bd8-8eb2-483f-aabd-c997ed512f03">Enteric bacteria eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enteric bacteria eradication (including gut flora): </b>Limited data available: Neonates: Oral: 50 to 100 mg/kg/day in divided doses every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4728950','lexi-content-ref-7151637','lexi-content-ref-Weimer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4728950','lexi-content-ref-7151637','lexi-content-ref-Weimer.1'])">Ref</a></span>). <b>Note:</b> Absorption from the GI tract may occur, particularly with prolonged duration of therapy; do not use longer than 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7151637','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7151637','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F200487"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosage expressed in terms of <b>neomycin sulfate</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1283532-3d6d-49ad-8037-448e1413032a">Cholangitis, prophylaxis of recurrent episodes after Kasai portoenterostomy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholangitis, prophylaxis of recurrent episodes after Kasai portoenterostomy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤3 years: Oral: 25 to 50 mg/kg/day in 4 divided doses 4 days per week; continue until 2 to 3 years of age. Dosing based on two small randomized trials and a small case series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12677572','lexi-content-ref-25534776','lexi-content-ref-8201512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12677572','lexi-content-ref-25534776','lexi-content-ref-8201512'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0f53bd8-8eb2-483f-aabd-c997ed512f03">Enteric bacteria eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enteric bacteria eradication (including gut flora): </b>Limited data available: <b>Note:</b> Use of neomycin for the treatment of enteric infection has been replaced by other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/day in divided doses every 6 to 8 hours; maximum daily dose: 12 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-4870512','lexi-content-ref-4728950','lexi-content-ref-AAP.2021','lexi-content-ref-Schleiss.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-4870512','lexi-content-ref-4728950','lexi-content-ref-AAP.2021','lexi-content-ref-Schleiss.1'])">Ref</a></span>); duration of treatment should not exceed 2 weeks due to GI absorption, which may result in systemic toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19888bf7-0eea-420c-a5c0-0f187b4242cc">Hepatic encephalopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic encephalopathy:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/day in divided doses every 6 hours for a maximum of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16494508','lexi-content-ref-1220606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16494508','lexi-content-ref-1220606'])">Ref</a></span>); maximum daily dose: 12 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d38075e1-39f4-4a72-9e69-c27c9fca2398">Surgical prophylaxis, colorectal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis, colorectal: </b>Limited data available: Infants, Children, and Adolescents: Oral: 15 mg/kg/dose for 3 doses administered over 10 hours (eg, at 1 PM, 2 PM, and 11 PM) the day before surgery as part of an appropriate combination regimen, with or without mechanical bowel preparation (consult institutional protocol); maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981','lexi-content-ref-20638534','lexi-content-ref-3093238','lexi-content-ref-26054862','lexi-content-ref-25818321','lexi-content-ref-24888857','lexi-content-ref-25598122','lexi-content-ref-Schleiss.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981','lexi-content-ref-20638534','lexi-content-ref-3093238','lexi-content-ref-26054862','lexi-content-ref-25818321','lexi-content-ref-24888857','lexi-content-ref-25598122','lexi-content-ref-Schleiss.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130678"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosing adjustments provided in the manufacturer's labeling; however, based on experience with aminoglycosides in pediatric patients, renal impairment increases the risk for toxicity, and consideration should be given to reducing the dose or discontinuing therapy. Dialyzable.</p></div>
<div class="block dohp drugH1Div" id="F51130679"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F200470"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9686" href="/d/html/9686.html" rel="external">see "Neomycin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0df229ca-c30a-4329-982e-e97cc7cedd51">Small intestinal bacterial overgrowth, methanogen overgrowth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small intestinal bacterial overgrowth, methanogen overgrowth (off-label use): Oral:</b> 500 mg twice daily, in combination with rifaximin, for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19996983','lexi-content-ref-24788320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19996983','lexi-content-ref-24788320'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d38075e1-39f4-4a72-9e69-c27c9fca2398">Surgical prophylaxis, colorectal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis, colorectal:</b>
<b>Oral:</b> 1 g at 1 PM, 2 PM, and 11 PM on the day preceding 8 AM surgery in combination with other appropriate agents and as an adjunct to mechanical cleansing of the intestine, followed by an appropriate IV antibiotic prophylaxis regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991827"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling; however, dosage reduction or discontinuation of therapy should be considered if a patient develops renal insufficiency. The risk of nephro- and/or ototoxicity is increased in patients with renal impairment. </p></div>
<div class="block doha drugH1Div" id="F50989108"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F200444"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (systemic contact dermatitis) (Carnicle 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis (Bolton 1979), malabsorption syndrome (with prolonged therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neurotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: State of neuromuscular blockade</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ototoxicity (including auditory ototoxicity and vestibular ototoxicity) (Ward 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory paralysis</p></div>
<div class="block coi drugH1Div" id="F200456"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to the neomycin or any component of the formulation; intestinal obstruction; patients with inflammatory or ulcerative GI disease.</p></div>
<div class="block war drugH1Div" id="F200441"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Cross-sensitivity to other aminoglycosides may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malabsorption: Small amounts of neomycin are absorbed through intact intestinal mucosa; increases in fecal bile acid excretion and reduction of intestinal lactase activity may occur. Oral doses of &gt;12 g/day produce malabsorption of fats, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin and iron.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular blockade and respiratory paralysis:<b> [US Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis; </b> especially when given soon after anesthesia or muscle relaxants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity; </b>symptoms also include numbness, skin tingling, muscle twitching and seizures. Usual risk factors include preexisting renal impairment and concomitant neuro-/nephrotoxic medications. Discontinue treatment if signs of ototoxicity occur; risk of hearing loss continues after drug withdrawal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hearing impairment: Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with preexisting renal insufficiency; dosage modification required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with genomic variants in <i>MT-RNR1</i>: Carriers of certain variants in the<i> MT-RNR1</i> gene (eg, m.1555A&gt;G) may be at increased risk for aminoglycoside-induced ototoxicity, including potentially significant hearing loss that may be irreversible, even when serum levels are within the normal range.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: More toxic than other aminoglycosides when given parenterally; <b>do not administer parenterally.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical irrigation: <b>Do not use as surgical irrigation</b> due to significant systemic absorption of the drug.</p></div>
<div class="block foc drugH1Div" id="F200451"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F200437"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524688"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Neomycin Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1.49 - $1.98</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53567923"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Each 500 mg neomycin sulfate tablet contains 350 mg of neomycin base.</p></div>
<div class="block admp drugH1Div" id="F52617885"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals; for surgical prophylaxis, administer at prescribed dosing times.</p></div>
<div class="block sts drugH1Div" id="F25226338"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20ºC to 25ºC (68ºF to 77ºF).</p></div>
<div class="block usep drugH1Div" id="F53567988"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct therapy (with erythromycin) for the suppression of normal bacterial flora of the bowel (eg, preoperative preparation); adjunct therapy for hepatic coma (portal-systemic encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract (All indications: FDA approved in ages ≥18 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F13299750"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F200446"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acarbose: Neomycin (Systemic) may enhance the adverse/toxic effect of Acarbose. Neomycin (Systemic) may decrease the metabolism of Acarbose. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the nephrotoxic effect of other Aminoglycosides. Aminoglycosides may enhance the neurotoxic effect of other Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides. Amphotericin B may enhance the neurotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): Neomycin (Systemic) may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: Aminoglycosides may enhance the neuromuscular-blocking effect of Botulinum Toxin-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CARBOplatin: May enhance the nephrotoxic effect of Aminoglycosides. Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalosporins: May enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides. CISplatin may enhance the neurotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.  Management: Avoid coadministration of colistimethate and aminoglycosides whenever possible due to the risk of nephrotoxicity and neuromuscular blockade. If coadministration cannot be avoided, monitor renal and neuromuscular function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclizine: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Neomycin (Systemic) may decrease the serum concentration of Methotrexate. Neomycin (Systemic) may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Ophthalmic): Aminoglycosides may enhance the nephrotoxic effect of Netilmicin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: May enhance the nephrotoxic effect of Aminoglycosides. Polymyxin B may enhance the neurotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: Neomycin (Systemic) may decrease serum concentrations of the active metabolite(s) of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Neomycin (Systemic) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Aminoglycosides may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides. Vancomycin may enhance the neurotoxic effect of Aminoglycosides. Management: Consider avoiding coadministration of aminoglycosides and vancomycin unless clinically indicated. If coadministered, monitor closely for signs of nephrotoxicity and neurotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Neomycin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5722064"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Aminoglycosides cross the placenta. Aminoglycosides may cause fetal harm if administered to a pregnant woman. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists. Large oral doses may cause malabsorption of some nutrients in the mother.</p></div>
<div class="block mopp drugH1Div" id="F53567969"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">During chronic or high-dose therapy: Renal function tests (serum creatinine, BUN, creatinine clearance); urinalysis (if clinical presentation indicates need); serial vestibular and audiometric tests.</p></div>
<div class="block rerp drugH1Div" id="F53567804"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Toxic serum concentrations: ≥1.5 mcg/ml (Marks 1973)</p></div>
<div class="block pha drugH1Div" id="F200440"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits</p></div>
<div class="block phk drugH1Div" id="F200455"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral, percutaneous: Poor (3%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 97% of an orally administered dose remains in the GI tract. Absorbed neomycin distributes to tissues and concentrates in the renal cortex. With repeated doses, accumulation also occurs in the inner ear.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 0% to 30%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak serum concentration: 1 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (97% of oral dose as unchanged drug); urine (30% to 50% of absorbed drug as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F200458"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Neomas bowers</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Neosulf</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Neomycine diamant</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Neomycin drossapharm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Neomicina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Neomicina salvat</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Neomycine diamant</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mycifradin | Neomycin | Nivemycin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Neomycin sulphate | Nivemycin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mycifradin | Neoate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mycerine</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Neobiotic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mycifradin | Neomycin | Nivemycin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Neomicina</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dexmy | Fradio</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Neomicina pisa | Neomixen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Neomycinum</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Neomycin amdipharm | Nivemycin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Neosulf</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Mycifradin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Neomycinum</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Neomicina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Neomycin Cortec | Neomycin Upjohn</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mycifradin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Myneocin | Neobemed | Neomycin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Neomycine diamant</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Neomycin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mycifradin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Abramowicz.1">
<a name="Abramowicz.1"></a>Abramowicz M. Antimicrobial Prophylaxis in Surgery. <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>. 16th ed. New York, NY: Medical Letter; 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7654476">
<a name="7654476"></a>Begg EJ, Barclay ML. Aminoglycosides - 50 Years On. <i>Br J Clin Pharmacol</i>. 1995;39(6):597-603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/7654476/pubmed" id="7654476" target="_blank">7654476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-526821">
<a name="526821"></a>Bolton RP. Clostridium difficile-associated colitis after neomycin treated with metronidazole. <i>Br Med J</i>. 1979;2(6203):1479-1480. doi:10.1136/bmj.2.6203.1479-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/526821/pubmed" id="526821" target="_blank">526821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20638534">
<a name="20638534"></a>Breckler FD, Rescorla FJ, Billmire DF. Wound infection after colostomy closure for imperforate anus in children: utility of preoperative oral antibiotics. <i>J Pediatr Surg</i>. 2010;45(7):1509-1513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/20638534/pubmed" id="20638534" target="_blank">20638534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12677572">
<a name="12677572"></a>Bu LN, Chen HL, Chang CJ, et al. Prophylactic oral antibiotics in prevention of recurrent cholangitis after the Kasai portoenterostomy.<i> J Pediatr Surg</i>. 2003;38(4):590-593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/12677572/pubmed" id="12677572" target="_blank">12677572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33456155">
<a name="33456155"></a>Carnicle JM, Tran TV, McKissack SS. Systemic contact dermatitis following oral neomycin therapy. <i>Proc (Bayl Univ Med Cent)</i>. 2020;34(1):89-90. doi:10.1080/08998280.2020.1805671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/33456155/pubmed" id="33456155" target="_blank">33456155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3093238">
<a name="3093238"></a>Debo Adeyemi S, Tai da Rocha-Afodu J. Clinical studies of 4 methods of bowel preparation in colorectal surgery. <i>Eur Surg Res</i>. 1986;18(5):331-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/3093238/pubmed" id="3093238" target="_blank">3093238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16494508">
<a name="16494508"></a>Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure. Potential for Pediatric Patients. <i>Pediatr Drugs</i>. 2006;8(1):1-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/16494508/pubmed" id="16494508" target="_blank">16494508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1943249">
<a name="1943249"></a>Edson RS, Terrell CL. The Aminoglycosides. <i>Mayo Clin Proc</i>. 1991;66(11):1158-1164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/1943249/pubmed" id="1943249" target="_blank">1943249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26054862">
<a name="26054862"></a>Feng C, Sidhwa F, Anandalwar S, et al. Contemporary practice among pediatric surgeons in the use of bowel preparation for elective colorectal surgery: A survey of the American Pediatric Surgical Association. <i>J Pediatr Surg</i>. 2015a;50(10):1636-1640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/26054862/pubmed" id="26054862" target="_blank">26054862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25818321">
<a name="25818321"></a>Feng C, Sidhwa F, Anandalwar S, et al. Variation in bowel preparation among pediatric surgeons for elective colorectal surgery: A problem of equipoise or a knowledge gap of the available clinical evidence? <i>J Pediatr Surg</i>. 2015b;50(6):967-971.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25818321/pubmed" id="25818321" target="_blank">25818321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4870512">
<a name="4870512"></a>Haltalin KC, Nelson JD, Hinton LV, Kusmiesz HT, Sladoje M. Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis. A double-blind study with ampicillin and neomycin. <i>J Pediatr</i>. 1968;72(5):708-720. doi:10.1016/s0022-3476(68)80021-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/4870512/pubmed" id="4870512" target="_blank">4870512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24411831">
<a name="24411831"></a>Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. <i>Mayo Clin Proc</i>. 2014;89(2):241-253. doi:10.1016/j.mayocp.2013.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/24411831/pubmed" id="24411831" target="_blank">24411831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25534776">
<a name="25534776"></a>Lien TH, Bu LN, Wu JF, et al. Use of <i>Lactobacillus casei</i> rhamnosus to prevent cholangitis in biliary atresia after kasai operation. <i>J Pediatr Gastroenterol Nutr</i>. 2015;60(5):654-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25534776/pubmed" id="25534776" target="_blank">25534776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1220606">
<a name="1220606"></a>Lovejoy FH, Bresnan MJ, Lombroso CT, et al. Anticerebral oedema therapy in Reye’s syndrome. <i>Archives of Disease in Childhood</i>. 1975;50:933-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/1220606/pubmed" id="1220606" target="_blank">1220606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19996983">
<a name="19996983"></a>Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.<i> J Clin Gastroenterol</i>. 2010;44(8):547-550. doi:10.1097/MCG.0b013e3181c64c90<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/19996983/pubmed" id="19996983" target="_blank">19996983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4728950">
<a name="4728950"></a>Marks MI, Shapera M, Brazeau M. Pediatric antimicrobial therapy III. <i>Canadian Medical Association Journal</i>. 1973;109:213-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/4728950/pubmed" id="4728950" target="_blank">4728950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201512">
<a name="8201512"></a>Mones RL, DeFelice AR, Preud’Homme D. Use of neomycin as the prophylaxis against recurrent cholangitis after Kasai portoenterostomy. <i>J Pediatric Surgery</i>. 1994;29(3):422-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/8201512/pubmed" id="8201512" target="_blank">8201512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7151637">
<a name="7151637"></a>Nation RL, Huang SM, Vidyasagar D, Reed M, Chiou WL. Absorption of oral neomycin in premature infants with suspected necrotizing enterocolitis. <i>Dev Pharmacol Ther</i>. 1982;5(1-2):53-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/7151637/pubmed" id="7151637" target="_blank">7151637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neomycin.1">
<a name="Neomycin.1"></a>Neomycin sulfate tablets [prescribing information]. Big Flats, NY: XGen Pharmaceuticals DJB Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24888857">
<a name="24888857"></a>Pennington EC, Feng C, St Peter SD, et al. Use of mechanical bowel preparation and oral antibiotics for elective colorectal procedures in children: is current practice evidence-based? <i>J Pediatr Surg</i>. 2014;49(6):1030-1035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/24888857/pubmed" id="24888857" target="_blank">24888857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788320">
<a name="24788320"></a>Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. <i>Dig Dis Sci</i>. 2014;59(6):1278-1285. doi:10.1007/s10620-014-3157-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/24788320/pubmed" id="24788320" target="_blank">24788320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32023228">
<a name="32023228"></a>Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. <i>Am J Gastroenterol</i>. 2020;115(2):165-178. doi:10.14309/ajg.0000000000000501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/32023228/pubmed" id="32023228" target="_blank">32023228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25598122">
<a name="25598122"></a>Rangel SJ, Islam S, St Peter SD, et al. Prevention of infectious complications after elective colorectal surgery in children: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee comprehensive review. <i>J Pediatr Surg</i>. 2015;50(1):192-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25598122/pubmed" id="25598122" target="_blank">25598122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schleiss.1">
<a name="Schleiss.1"></a>Schleiss MR. Principles of antibacterial therapy. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 207.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25042402">
<a name="25042402"></a>Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. <i>Hepatology</i>. 2014;60(2):715-735. doi:10.1002/hep.27210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25042402/pubmed" id="25042402" target="_blank">25042402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-646289">
<a name="646289"></a>Ward KM, Rounthwaite FJ. Neomycin ototoxicity. <i>Ann Otol Rhinol Laryngol</i>. 1978;87(2 Pt 1):211-215. doi:10.1177/000348947808700211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/646289/pubmed" id="646289" target="_blank">646289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weimer.1">
<a name="Weimer.1"></a>Weimer KE, Singh T, Permar SR. Viral infections. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022:chap. 48.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12634 Version 318.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
